Group 1: Company Overview and Recent Activities - Zhejiang Zoli Pharmaceutical Co., Ltd. held investor relations activities including site visits and conference calls with various securities firms and investment entities [1][2]. - The management team provided a brief overview of recent operational performance and the acquisition of the future pharmaceutical asset group [2]. Group 2: Acquisition Details - The acquired asset group includes multiple products, notably "Multiple Trace Element Injection (I)" and "Multiple Trace Element Injection (II)", which focus on parenteral nutrition and have established a strong academic brand in pediatric and maternal health [2][3]. - The asset group achieved a net profit of CNY 45.79 million from January to September 2025, indicating strong profitability [2]. Group 3: Product Pipeline and Regulatory Outlook - The "Multiple Trace Element Injection (III)" is currently under technical review and is expected to be approved in 2026, enhancing the company's product line in adult trace elements [3]. - The new version of the National Essential Medicines List is likely to prioritize pediatric medications, increasing the chances of the company's products being included [3]. Group 4: Synergy and Market Strategy - The integration of the acquired asset group is expected to leverage existing sales channels, with over 15,000 hospitals covered by Zoli's core product, enhancing market penetration [4]. - The company plans to utilize its market advantages in centralized procurement and essential medicines to facilitate the sales of the new products across more than 20 provinces [4]. Group 5: Production Capacity and Future Plans - Current production capacity for the core product, Wuling Capsule, is 900 tons, with high utilization rates. The company is planning to expand capacity to meet future demand [5]. - The "Wuling+X" product development project aims to create a family of 10 innovative products targeting digestive and urological conditions [5]. Group 6: Sales Projections and Market Trends - For 2026, Wuling Capsule is expected to maintain steady growth through enhanced distribution in county-level medical institutions and online channels, with a focus on consumer education [6]. - The Bailing series is projected to achieve a sales scale of CNY 1 billion, supported by participation in national centralized procurement across 31 provinces [6]. Group 7: Financial Strategy and Shareholder Returns - The acquisition will be financed through phased cash payments, with the company maintaining a stable dividend policy in line with profit distribution principles [10][11].

Group 1: Company Overview - Fujian Snowman Group Co., Ltd. was established in 2000, focusing on thermal power technology for cold chain logistics, industrial refrigeration, clean energy, and hydrogen power sectors [1] - In the first three quarters of 2025, the company achieved a revenue of CNY 1.631 billion, representing a year-on-year increase of 24.26% [1] Group 2: Data Center Business Expansion - The company has entered the data center business through compressor refrigeration equipment supply and key project construction [1] - It offers a diverse product line including piston compressors, open screw compressors, semi-hermetic screw compressors, and centrifugal compressors, with a new centrifugal compressor designed for high-efficiency data centers now on the market [1] - The company utilizes low-charge ammonia refrigeration technology, replacing traditional refrigerants, exemplified by its provision of third-generation low-charge ammonia cooling technology to Facebook's Denmark data center [1][2] Group 3: Controlled Nuclear Fusion Business - The company produces helium compressors essential for large-scale low-temperature systems, crucial for projects like the superconducting tokamak [2] - Its "megawatt-level" helium compressors can achieve cooling capacities at -271°C, with the technology recognized as internationally leading [2] Group 4: Hydrogen Energy Sector - The company is developing hydrogen fuel cell technology, focusing on core components and systems, while extending its existing compressor and refrigeration technologies to liquid hydrogen applications [2] - It has established a global hydrogen fuel cell technology R&D and supply chain system, with research institutions in Europe and Japan [2] - The new generation of metal plate fuel cell stacks has been developed, and the company is advancing the mass production of hydrogen fuel cells and core components domestically [2]

Group 1: Business Collaborations and Revenue Generation - The company has secured compliance data service business orders from major domestic and international AI model companies, including Alibaba, Tencent, and Microsoft, for model training purposes [2] - The company is a primary supplier of multimodal data for Tencent's mixed Yuan model and has established a partnership with Microsoft that includes both compliance data for exclusive model training and copyright material integration [2] - The company has launched a creative ToB custom service platform that integrates with top global models like Midjourney and nanobanana, facilitating various content generation services [2] Group 2: Data Resources and Industry Position - The company possesses over 700 million high-quality, copyright-compliant content data for AI model training, leading the industry [4] - It has a comprehensive structured metadata system with 3 million structured tags and industry knowledge graphs, providing a solid foundation for compliant training and commercial applications [4] - The company emphasizes that the demand for high-quality copyright data will continue to grow as AI models evolve, positioning itself as a key player in the generative AI value chain [4] Group 3: Content Monetization and IP Management - The company is actively exploring IP revenue-sharing models in collaboration with major platforms, recognizing the importance of high-quality compliant content for monetization opportunities [4][5] - Strategic partnerships have been established with platforms like Vidu and Jianying, allowing the company to provide authorized content to users beyond the Jianying platform [4] - The company aims to enhance its collaboration with generative AI platforms to explore IP licensing management and content revenue-sharing models [5]

Group 1: Investor Relations Activity Overview - The investor relations activity involved a specific audience survey with three investors participating: Jianxin Pension (Tao Jin, Cao Jingyi) and Changjiang Securities (Li Jin) [2] - The meeting took place on December 15, 2025, at the company's headquarters [2] - Company representatives included Chairman and General Manager Zhou Zongwen, Board Secretary and Deputy General Manager He Xiaolin, and Securities Affairs Representative Rong Huan [2] Group 2: Key Discussion Topics - Investors inquired about industry conditions, brand matrix, national treasures, product structure, terminal sales performance, and dividend planning [2] - The company ensured compliance with the Information Disclosure Management System, maintaining the accuracy, completeness, and timeliness of disclosed information [2] - Investors signed a commitment letter as per Shenzhen Stock Exchange requirements during the on-site survey [2]

Company Overview - Guangdong Boying Special Welding Technology Co., Ltd. was established in 2007, initially focusing on welding services for offshore drilling platforms for North American clients. The company has since expanded into anti-corrosion and wear-resistant welding fields and successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market in July 2023 [1]. - The company emphasizes advanced welding technology and provides manufacturing services and process solutions to clients [1]. Market Strategy - The company aims to maintain its leading position in the domestic market while actively exploring overseas markets, particularly by investing in a production base in Vietnam to seize opportunities in the North American HRSG market [1]. - The demand for waste incineration and the transformation of the coal-fired power generation industry are expected to enhance market penetration rates, with significant growth potential in chemical, metallurgy, and paper industries [1]. Business Development - The company has proactively laid out HRSG and oil-gas composite pipe businesses, with HRSG already achieving a certain scale of production and securing some orders. Potential clients are currently undergoing factory audits [2]. - The new production base in Vietnam has commenced operations, with a second phase under construction. The Dawa production base is also progressing, expected to be operational next year [2]. Competitive Landscape - In the Vietnamese HRSG market, competitors include manufacturers from South Korea, Thailand, and Vietnam. The company has extensive experience in the energy sector and has established a production line in Vietnam, providing a cost advantage over foreign competitors [3]. - The production cycle for HRSG products is approximately six months, with the Vietnam base primarily producing components for gas turbine heat recovery systems [3][4]. Production Capacity - One HRSG production line in Vietnam can produce about two sets of HRSG devices per year, depending on production scheduling and resource availability [4]. - The company has obtained necessary certifications, including ASME, and is progressing well in the customer audit process for entering the North American market [5]. Industry Applications - The company's main business includes anti-corrosion and wear-resistant welding equipment, non-welded boiler components, pressure vessels, and high-end steel structures, applicable in energy, chemical, metallurgy, and paper industries [6][7]. - The company has established relationships with high-quality clients in various sectors, including paper and metallurgy, further solidifying its leading position in the industrial anti-corrosion and wear-resistant market [6].

Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey [2] - Participants included representatives from Shenzhen Century Quantum and various other individuals [2] - The meeting took place on December 12, 2025, at the company's headquarters [2] Group 2: Purpose of the Meeting - The main objective was to understand the company's production and operational status [2]

Group 1: Investor Meeting Overview - The investor meeting was attended by 32 participants from various institutions, including Hongsike Asset, Guangzhou Shuncong Investment, and Shenzhen Qichuang Group [1] - The meeting took place on December 12, 2025, at the company's headquarters [1] - The reception was managed by the investor relations team, specifically Zhang Yu and Yang Kexin [1] Group 2: Meeting Purpose - The primary focus of the meeting was to understand the company's production and operational status [1]

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical business group achieved a main business revenue of CNY 4.751 billion, a year-on-year increase of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded CNY 1.453 billion, with a significant year-on-year growth of over 20.9% [2] - Other traditional Chinese medicine products showed remarkable growth, with sales of Canling Jianpi Granules exceeding CNY 100 million and Pudilan Anti-inflammatory Tablets nearing CNY 100 million [2] Group 2: Online Sales and Marketing - The pharmaceutical business group expanded its online market, with O2O sales increasing by over 20% year-on-year [3] - During the 2025 "618" shopping festival, the company’s main products ranked significantly higher on the regular medicine list [3] - E-commerce platforms attracted 48.45 million visitors, resulting in 3.54 million consumers and generating a GMV of CNY 254 million [3] Group 3: Health Products Strategy - The health products group aims to become a leader in high-quality health lifestyle products, focusing on oral care and hair care [4] - Continuous enhancement of oral product advantages and rapid scaling of hair care business are key objectives for the second half of the year [4] Group 4: Nuclear Medicine Development - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 60 subjects enrolled [5] - The INR102 therapeutic nuclear medicine project has received clinical trial approval, with 12 patients enrolled in Phase I trials [5] Group 5: Traditional Chinese Medicine Resource Development - The Chinese medicine resource group focuses on Yunnan's local medicinal materials, achieving significant results through collaborative efforts [6] - The establishment of 14 seed source bases and the completion of 90% of the annual target for quality seed promotion [6] - The digital cloud medicine platform achieved a transaction volume exceeding CNY 1 billion, with 18,000 registered farmers [6] Group 6: Future Directions for Provincial Pharmaceutical Company - The provincial pharmaceutical company plans to enhance market share in existing hospitals and distribution channels while exploring new growth areas [8] - Strategies include optimizing supply chain management and improving accounts receivable and inventory structure [8]

Group 1: Marketing and Sales Performance - In the first half of 2025, the pharmaceutical business group achieved over 20% year-on-year growth in O2O sales, leveraging platforms like Douyin and Xiaohongshu for extensive content marketing [2][3] - Online sales reached a GMV of 254 million CNY, with 48.45 million visitors and 3.54 million consumers driven to e-commerce platforms [3] - The company’s strategic partnership with JD Health significantly improved the ranking of its main products during the 2025 618 shopping festival [3] Group 2: Traditional Chinese Medicine (TCM) Resource Development - The TCM resource business group generated 914 million CNY in external revenue in the first half of 2025, reflecting a year-on-year growth of approximately 6.3% [4] - The group implemented a "six unifications" operational model to enhance the TCM supply chain, focusing on unified planting, sourcing, standards, processing, sales, and management [4] Group 3: Research and Development Progress - The company is advancing 16 major TCM projects, with 37 ongoing initiatives, focusing on secondary development and innovative drug creation [6] - Clinical trials for key products like Qixuekang and Gongxuening are progressing, with significant milestones achieved in various phases of testing [6] Group 4: Dividend Distribution - For the 2024 fiscal year, the company announced a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.16 billion CNY, which represents 90.09% of the net profit attributable to shareholders [7] - In the first half of 2025, a cash dividend of 10.19 CNY per 10 shares was distributed, amounting to 1.82 billion CNY, which is 50.05% of the net profit for that period [8] Group 5: Digital Transformation Initiatives - The company is implementing a digital development plan (2022-2026) that integrates data and AI across key operational areas, enhancing efficiency and innovation [9][10] - A self-developed marketing operations platform has improved channel efficiency, reducing manual processing workload by 30% and eliminating 60,000 paper documents annually [9] - The digitalization of the TCM supply chain has significantly reduced transaction times from one day to mere minutes, enhancing overall operational efficiency [11]

Group 1: Commercial Space Business Development - The company is conducting feasibility studies for the production line of commercial rocket fuel tanks, focusing on compatibility and investment efficiency based on market trends and customer needs [2] - The maturity of reusable technology is expected to enhance launch frequency and operational efficiency, leading to increased demand for new rocket structures, thus creating new business growth opportunities [4] - The company is actively expanding its customer base in the commercial space sector and has made substantial progress, with new customer orders expected to enter mass cooperation in Q1 of the following year [4] Group 2: Manufacturing Capabilities and Market Position - The company completed the construction of a riveting production line in the first half of 2024, with an annual capacity of 10 units, and is prepared to expand capacity based on order demand [4] - The manufacturing of rocket structural components is currently constrained by supply, with a limited number of suppliers capable of large-scale delivery, indicating a strong market position for the company [5] - The company has established stable, small-batch product deliveries to leading private rocket companies, leveraging its experienced team and financial resources for equipment purchases and production line construction [5] Group 3: Aerospace and Automotive Business Performance - The aerospace business has shown improvement due to recovering customer demand and product optimization, with ongoing efforts to enhance production organization and delivery capabilities [6] - The automotive sector has experienced stable revenue growth, although profit margins have fluctuated due to material cost increases and depreciation from new projects [7] - The company anticipates enhanced profitability in the automotive sector by 2026, driven by optimized capacity structure and increased high-value product ratios [8] Group 4: Growth Drivers in Automotive Sector - Key growth drivers for the automotive business include expanding exports, new customer development, product category expansion, and increased industry concentration [8] - Strategic partnerships with international suppliers like Magna, Valeo, and Bosch provide a solid foundation for overseas market expansion [8]